MEDIF
MediPharm Labs Corp.
OTC Markets OTCQBUSDEQUITY
Healthcare
DELAYED
Last price
0.06
■ 0.00 (0.00%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
0.05
Prev close
0.06
Day high
0.06
Day low
0.06
Volume
8.70K
Market cap
$24.35M
P/E (TTM)
—
52W range
0.04 – 0.08
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
49.71M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 9, 26 | Bumby (Michael Scott) Director of Issuer |
— | 176.78K | — | Direct |
| Jun 9, 26 | Halyk (Christopher John) Director of Issuer |
— | 98.21K | — | Direct |
| Jun 9, 26 | Hunter (Gregory Edison) Senior Officer of Issuer |
— | 183.21K | — | Direct |
| Jun 9, 26 | Jameson (Emily) Director of Issuer |
— | 98.21K | — | Direct |
| Jun 9, 26 | Medland (John) Director of Issuer |
— | 88.39K | — | Direct |
| Jun 9, 26 | Pidduck (David) Director of Issuer |
— | 302.14K | — | Direct |
| Jun 9, 26 | Taves (Christopher David) Director of Issuer |
— | 392.86K | — | Direct |
| Jun 9, 26 | Taves (Christopher David) Director of Issuer |
SELL | 176.79K | $9.55K | Direct |
| Jan 1, 26 | Bumby (Michael Scott) Director of Issuer |
— | 0 | — | Direct |
| Dec 9, 25 | Bumby (Michael Scott) Director of Issuer |
— | 82.98K | — | Direct |
| Dec 9, 25 | Halyk (Christopher John) Director of Issuer |
— | 82.98K | — | Direct |
| Dec 9, 25 | Hunter (Gregory Edison) Senior Officer of Issuer |
— | 589.43K | — | Direct |
| Dec 9, 25 | Jameson (Emily) Director of Issuer |
— | 32.63K | — | Direct |
| Dec 9, 25 | Medland (John) Director of Issuer |
— | 32.63K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Bumby (Michael Scott) |
Director of Issuer | 637.88K | Exercise of rights |
Halyk (Christopher John) |
Director of Issuer | 528.91K | Exercise of rights |
Hunter (Gregory Edison) |
Senior Officer of Issuer | 3.09M | Exercise of rights |
Jameson (Emily) |
Director of Issuer | 163.48K | Exercise of rights |
Medland (John) |
Director of Issuer | 253.66K | Exercise of rights |
Pidduck (David) |
Director of Issuer | 22.79M | Exercise of rights |
Potts (Shelley Donne) |
Director of Issuer | 310.22K | Exercise of rights |
Strachan (Keith) |
Director of Issuer | 3.65M | Exercise of rights |
Taves (Christopher David) |
Director of Issuer | 3.02M | Exercise of rights |
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
+3.64%
+5.0%
1M
0.00%
-3.7%
3M
-5.00%
-8.1%
6M
+11.76%
+0.7%
YTD
+11.76%
-0.5%
1Y
0.00%
-20.0%
3Y
+1.79%
-72.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$24.35M
Enterprise value$14.40M
Revenue (TTM)$41.46M
Gross profit$13.14M
EBITDA$-2.41M
Net income$-4.97M
EPS (TTM)$-0.01
Free cash flow$2.06M
Total cash$10.42M
Total debt$421.00K
Book value / share$0.06
Shares outstanding427.18M
Float390.00M
Short % of float—
Dividend yield—
Beta (5Y)0.93
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book0.95
EV / revenue0.35
EV / EBITDA-5.97
Gross margin31.70%
Operating margin0.82%
Profit margin-12.00%
Return on equity-13.22%
Return on assets-5.17%
Debt / equity1.19
Current ratio2.69
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $45.12M | $41.96M | $33.06M | $22.12M | — | +7.5% |
| Operating revenue | $48.13M | $45.20M | $36.82M | $24.98M | — | +6.5% |
| Cost of revenue | $31.16M | $29.16M | $27.21M | $24.03M | — | +6.9% |
| Gross profit | $13.97M | $12.80M | $5.86M | -$1.91M | — | +9.1% |
| Research & development | $223.00K | $235.00K | $209.00K | $1.00M | — | -5.1% |
| Selling, general & admin | $21.48M | $22.86M | $24.80M | $24.76M | — | -6.0% |
| Total operating expense | $22.38M | $23.70M | $23.60M | $26.87M | — | -5.6% |
| Operating income | -$8.41M | -$10.89M | -$17.75M | -$28.78M | — | +22.8% |
| Net interest income | $169.00K | $115.00K | $475.00K | $448.00K | — | +47.0% |
| Pre-tax income | -$8.27M | -$10.69M | -$13.36M | -$29.99M | — | +22.7% |
| Tax provision | — | $0 | -$276.00K | -$6.00K | $113.00K | — |
| Net income | -$8.27M | -$10.69M | -$13.08M | -$29.98M | — | +22.7% |
| Net income to common | -$8.27M | -$10.69M | -$13.08M | -$29.98M | — | +22.7% |
| Basic EPS | -0.02 | -0.03 | -0.04 | -0.11 | — | +33.3% |
| Diluted EPS | -0.02 | -0.03 | -0.04 | -0.11 | — | +33.3% |
| EBIT | -$8.20M | -$10.12M | -$12.99M | -$29.96M | — | +18.9% |
| EBITDA | -$6.54M | -$7.52M | -$10.48M | -$27.09M | — | +13.0% |
| Basic shares | 418.32M | 407.99M | 363.32M | 276.86M | — | +2.5% |
| Diluted shares | 418.32M | 407.99M | 363.32M | 276.86M | — | +2.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $10.81M | $11.69M | $17.98M | $24.14M | -7.6% |
| Cash & short-term investments | $10.81M | $11.69M | $17.98M | $24.14M | -7.6% |
| Accounts receivable | $6.77M | $6.88M | $5.51M | $12.35M | -1.6% |
| Inventory | $8.02M | $8.71M | $9.90M | $7.78M | -7.9% |
| Total current assets | $27.47M | $33.08M | $36.63M | $47.34M | -17.0% |
| Property, plant & equipment | $17.60M | $19.16M | $25.27M | $18.11M | -8.2% |
| Goodwill & intangibles | $675.00K | $854.00K | $1.03M | $39.00K | -21.0% |
| Total assets | $45.74M | $53.73M | $63.94M | $65.50M | -14.9% |
| Total current liabilities | $9.93M | $10.49M | $10.86M | $9.46M | -5.4% |
| Current debt | $150.00K | $258.00K | $2.10M | $523.00K | -41.9% |
| Total debt | $201.00K | $388.00K | $2.29M | $632.00K | -48.2% |
| Total liabilities | $9.93M | $10.55M | $10.93M | $9.49M | -5.9% |
| Retained earnings | -$169.38M | -$187.43M | -$176.73M | -$163.65M | +9.6% |
| Shareholder equity | $35.81M | $43.18M | $53.01M | $56.01M | -17.1% |
| Working capital | $17.54M | $22.59M | $25.77M | $37.89M | -22.3% |
| Net tangible assets | $35.14M | $42.33M | $51.97M | $55.97M | -17.0% |
| Shares issued | 424.86M | 415.05M | 401.40M | 282.16M | +2.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$8.27M | -$10.69M | -$13.08M | -$29.98M | +22.7% |
| Depreciation & amortisation | $1.66M | $2.60M | $2.52M | $2.87M | -36.2% |
| Stock-based compensation | $1.34M | $976.00K | $2.03M | $2.87M | +37.7% |
| Change in working capital | -$25.00K | $1.65M | $3.45M | $6.24M | -101.5% |
| Operating cash flow | -$5.50M | -$4.86M | -$12.34M | -$16.07M | -13.2% |
| Capital expenditure | -$100.00K | -$154.00K | -$471.00K | -$863.00K | +35.1% |
| Investing cash flow | $4.62M | $413.00K | $6.87M | $5.16M | +1,018.6% |
| Dividends paid | $0 | $0 | $0 | $0 | — |
| Financing cash flow | -$18.00K | -$1.85M | -$368.00K | $796.00K | +99.0% |
| Free cash flow | -$5.60M | -$5.01M | -$12.81M | -$16.93M | -11.7% |
| End cash position | $10.81M | $11.69M | $17.98M | $24.14M | -7.6% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $8.96M | $11.06M | $11.45M | $11.81M | $10.81M | — | -19.0% |
| Operating revenue | $9.61M | $11.77M | $12.22M | $12.61M | $11.53M | — | -18.4% |
| Cost of revenue | $5.64M | $7.17M | $8.89M | $8.48M | $6.16M | — | -21.3% |
| Gross profit | $3.32M | $3.89M | $2.56M | $3.33M | $4.64M | — | -14.7% |
| Research & development | $24.00K | $52.00K | $47.00K | $46.00K | $78.00K | — | -53.8% |
| Selling, general & admin | $4.29M | $5.08M | $4.51M | $7.16M | $5.19M | — | -15.5% |
| Total operating expense | $4.23M | $5.87M | $4.75M | $7.13M | $5.08M | — | -27.9% |
| Operating income | -$912.00K | -$1.98M | -$2.19M | -$3.80M | -$441.00K | — | +53.9% |
| Net interest income | $45.00K | $39.00K | $46.00K | $30.00K | $54.00K | — | +15.4% |
| Pre-tax income | -$867.00K | -$1.97M | -$2.14M | -$3.77M | -$387.00K | — | +55.9% |
| Tax provision | — | — | — | — | — | $0 | — |
| Net income | -$867.00K | -$1.97M | -$2.14M | -$3.77M | -$387.00K | — | +55.9% |
| Net income to common | -$867.00K | -$1.97M | -$2.14M | -$3.77M | -$387.00K | — | +55.9% |
| Basic EPS | 0.00 | — | -0.01 | -0.01 | 0.00 | — | — |
| Diluted EPS | 0.00 | — | -0.01 | -0.01 | 0.00 | — | — |
| EBIT | -$852.00K | -$1.95M | -$2.13M | -$3.76M | -$371.00K | — | +56.3% |
| EBITDA | -$470.00K | -$1.55M | -$1.71M | -$3.34M | $54.00K | — | +69.7% |
| Basic shares | 424.86M | 424.86M | 420.76M | 415.35M | 415.12M | — | 0.0% |
| Diluted shares | 424.86M | 424.86M | 420.76M | 415.35M | 415.12M | — | 0.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $9.87M | $10.81M | $10.58M | $10.36M | $8.44M | — | -8.7% |
| Cash & short-term investments | $9.87M | $10.81M | $10.58M | $10.36M | $8.44M | — | -8.7% |
| Accounts receivable | $5.77M | $6.77M | $6.62M | $7.04M | $7.41M | — | -14.7% |
| Inventory | $8.47M | $8.02M | $8.10M | $9.35M | $10.59M | — | +5.6% |
| Total current assets | $25.73M | $27.47M | $27.93M | $29.52M | $31.80M | — | -6.3% |
| Property, plant & equipment | $17.26M | $17.60M | $17.95M | $18.49M | $18.82M | — | -1.9% |
| Goodwill & intangibles | $630.00K | $675.00K | $720.00K | $764.00K | $809.00K | — | -6.7% |
| Total assets | $43.62M | $45.74M | $46.60M | $49.31M | $52.07M | — | -4.6% |
| Total current liabilities | $8.52M | $9.93M | $8.74M | $9.48M | $8.80M | — | -14.2% |
| Current debt | — | $150.00K | $351.00K | $450.00K | $14.00K | $258.00K | — |
| Total debt | $18.00K | $201.00K | $423.00K | $542.00K | $125.00K | — | -91.0% |
| Total liabilities | $8.52M | $9.93M | $8.74M | $9.49M | $8.84M | — | -14.2% |
| Retained earnings | -$170.25M | -$169.38M | -$188.63M | -$186.49M | -$187.81M | — | -0.5% |
| Shareholder equity | $35.10M | $35.81M | $37.86M | $39.82M | $43.23M | — | -2.0% |
| Working capital | $17.21M | $17.54M | $19.19M | $20.04M | $23.00M | — | -1.9% |
| Net tangible assets | $34.47M | $35.14M | $37.14M | $39.05M | $42.42M | — | -1.9% |
| Shares issued | 424.86M | 424.86M | 420.76M | 420.76M | 415.14M | — | 0.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$867.00K | -$1.97M | -$2.14M | -$3.77M | -$387.00K | — | +55.9% |
| Depreciation & amortisation | $382.00K | $396.00K | $420.00K | $419.00K | $425.00K | — | -3.5% |
| Stock-based compensation | $154.00K | $211.00K | $194.00K | $502.00K | $437.00K | — | -27.0% |
| Change in working capital | -$595.00K | $1.73M | $1.37M | $272.00K | -$3.40M | — | -134.4% |
| Operating cash flow | -$824.00K | $435.00K | -$158.00K | -$2.77M | -$3.01M | — | -289.4% |
| Capital expenditure | -$1.00K | — | -$16.00K | -$42.00K | -$42.00K | -$44.00K | — |
| Investing cash flow | -$1.00K | $0 | $459.00K | $4.20M | -$42.00K | — | — |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | — | — |
| Financing cash flow | -$138.00K | -$183.00K | -$73.00K | $447.00K | -$209.00K | — | +24.6% |
| Free cash flow | -$825.00K | $435.00K | -$174.00K | -$2.81M | -$3.05M | — | -289.7% |
| End cash position | $9.87M | $10.81M | $10.58M | $10.36M | $8.44M | — | -8.7% |
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders11.64%
Held by institutions0.00%
Institutions holding1
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.06
+3.45% from price
SMA 20
0.05
+4.59% from price
SMA 50
0.05
+6.03% from price
SMA 100
0.06
+3.45% from price
SMA 200
0.05
+7.80% from price
EMA 12
0.06
+3.15% from price
EMA 26
0.05
+3.96% from price
EMA 50
0.05
+4.18% from price
RSI (14)
61.7
Neutral
MACD (12,26,9)
0.00
Hist 0.00
ATR (14)
0.00
6.77% of price
Realised vol 30D
47.7%
Annualised
Bollinger upper
0.06
20, 2σ
Bollinger lower
0.05
20, 2σ
50 / 200 cross
Golden
0.05 vs 0.05
Trend bias
Above 200
+7.80%
Risk profile
Beta vs SPY
-0.05
Less volatile than market
Correlation to SPY
-0.01
Largely independent
Realised vol 30D
47.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-27.6%
Peak to trough
Max drawdown 5Y
-85.3%
Peak to trough
ATR 14
0.00
6.77% of price
Beta (reported)
0.93
5Y monthly, from filing
Headlines
MediPharm Labs Corp (MEDIF) (Q2 2026) Earnings Call Highlights: First Profitable Quarter Since ...
GuruFocus.com · 9d ago
MediPharm Labs Reports Positive Q2 2026 Net Income and Second Consecutive Quarter of Positive Adjusted EBITDA
GlobeNewswire · 9d ago
MediPharm Labs Sets Date to Report Second Quarter 2026 Financial Results
GlobeNewswire · 12d ago
MediPharm Reports Positive Phase 2 LiBBY Trial Results in Patients With Advanced Dementia
MT Newswires · 39d ago
MediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer’s Disease and Dementia
GlobeNewswire · 39d ago
MediPharm Labs Announces Voting Results from the 2026 Annual and Special Meeting of Shareholders
GlobeNewswire · 66d ago
MediPharm Labs Reminds Shareholders of Upcoming Annual and Special Meeting
GlobeNewswire · 86d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.